HZNP Horizon Therapeutics Public Limited Company Stock Quote

HZNP [NASD]

Horizon Therapeutics Public Limited Company

Healthcare | Drug Manufacturers - General | Ireland

Index	-	P/E	56.32	EPS (ttm)	1.63	Insider Own	0.90%	Shs Outstand	220.63M	Perf Week	9.73%
Market Cap	20.52B	Forward P/E	17.57	EPS next Y	5.23	Insider Trans	-23.57%	Shs Float	217.89M	Perf Month	25.68%
Income	389.80M	PEG	1.98	EPS next Q	0.27	Inst Own	92.20%	Short Float	3.00%	Perf Quarter	33.40%
Sales	2.20B	P/S	9.32	EPS this Y	-37.60%	Inst Trans	2.29%	Short Ratio	2.58	Perf Half Y	25.34%
Book/sh	18.25	P/B	5.04	EPS next Y	38.90%	ROA	7.50%	Target Price	113.00	Perf Year	168.59%
Cash/sh	9.32	P/C	9.86	EPS next 5Y	28.40%	ROE	12.60%	52W Range	23.81 - 96.54	Perf YTD	25.65%
Dividend	-	P/FCF	53.18	EPS past 5Y	48.20%	ROI	8.90%	52W High	-4.80%	Beta	1.09
Dividend %	-	Quick Ratio	3.40	Sales past 5Y	23.80%	Gross Margin	75.80%	52W Low	286.01%	ATR	4.36
Employees	1395	Current Ratio	3.50	Sales Q/Q	105.00%	Oper. Margin	20.80%	RSI (14)	60.00	Volatility	5.92% 4.78%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-71.50%	Profit Margin	17.70%	Rel Volume	0.58	Prev Close	90.91
Shortable	Yes	LT Debt/Eq	0.25	Earnings	Feb 24 BMO	Payout	0.00%	Avg Volume	2.53M	Price	91.91
Recom	1.70	SMA20	6.43%	SMA50	15.91%	SMA200	31.72%	Volume	1,474,104	Change	1.10%

Sep-09-20

Initiated

JP Morgan

Overweight

$110

Aug-27-20

Initiated

Citigroup

Buy

$112

Jan-08-20

Initiated

Goldman

Neutral

$35

Sep-26-19

Initiated

BofA/Merrill

Buy

$34

Sep-12-19

Initiated

Guggenheim

Buy

Aug-14-19

Upgrade

BMO Capital Markets

Market Perform → Outperform

$29 → $36

May-01-19

Upgrade

Citigroup

Neutral → Buy

$21 → $32

Mar-08-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$32

Nov-15-18

Downgrade

Mizuho

Buy → Neutral

Jun-27-18

Downgrade

Citigroup

Buy → Neutral

Jan-12-18

Upgrade

Mizuho

Neutral → Buy

$12 → $18

Sep-28-17

Initiated

Goldman

Buy

$16

Jun-16-17

Initiated

Cantor Fitzgerald

Overweight

$13

May-09-17

Reiterated

Stifel

Buy

$35 → $20

May-09-17

Downgrade

Mizuho

Buy → Neutral

$22 → $10

Feb-28-17

Reiterated

Mizuho

Buy

$25 → $22

Dec-16-16

Upgrade

Mizuho

Neutral → Buy

$14 → $25

Dec-09-16

Downgrade

Mizuho

Buy → Neutral

$30 → $14

Nov-28-16

Upgrade

Citigroup

Neutral → Buy

Nov-08-16

Reiterated

Mizuho

Buy

$29 → $30

Feb-26-21 04:05PM	Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference Business Wire
Feb-25-21 04:05PM	Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish® Business Wire -5.14%
03:27PM	Horizon Therapeutics USA, Inc. -- Moody's: Horizon's term loan upsizing modestly credit negative Moody's
12:03PM	Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96 Investor's Business Daily
Feb-24-21 04:41PM	Horizon Posts Triple-Digit Sales Growth After Adding Tepezza To Lineup Investor's Business Daily +13.29%
04:11PM	Top Healthcare Stocks for March 2021 Investopedia
11:01AM	Top-Ranked Horizon Therapeutics Hits Key RS Rating Benchmark Investor's Business Daily
07:00AM	Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance Business Wire
Feb-22-21 09:30AM	New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase Business Wire -5.75%
Feb-20-21 08:33PM	(VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are Shareholders Getting a Fair Deal? PR Newswire
Feb-18-21 01:08PM	Inovio Pharmaceuticals Shows Market Leadership With Jump To 86 RS Rating Investor's Business Daily
Feb-17-21 12:44PM	Co-Diagnostics Clears Technical Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
Feb-10-21 01:40PM	Heat Biologics Stock Notches Scorching RS Rating Investor's Business Daily
Feb-04-21 01:54PM	Anavex Life Sciences Crp Earns 94 RS Rating; Soars To Record High Investor's Business Daily
Feb-03-21 12:53PM	Horizon Pharma Shows Rising Price Performance With Jump To 85 RS Rating Investor's Business Daily
08:00AM	Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021 Business Wire
Feb-02-21 07:40AM	Horizon To Snap Up Viela Bio For $3B; Shares Climb SmarterAnalyst +9.67%
Feb-01-21 03:12PM	SHAREHOLDER ALERT: WeissLaw LLP Investigates Viela Bio, Inc. PR Newswire +6.29%
02:57PM	Horizon Pharma Sees Rising Composite Rating To 96 Investor's Business Daily
02:05PM	VIELA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of VIE and Encourages Investors to Contact the Firm GlobeNewswire
09:36AM	(VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are Shareholders Getting a Fair Deal? PR Newswire
07:27AM	UPDATE: Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion MarketWatch
07:00AM	Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio Business Wire
Jan-26-21 03:39PM	Composite Rating For Pacira Pharmaceuticals Rises To 97 Investor's Business Daily
01:42PM	Dow Jones, S&P 500 Up Slightly After Giving Up Gains; Microsoft In Buy Zones Ahead Of Earnings Investor's Business Daily
Jan-20-21 12:45PM	Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97 Investor's Business Daily
Jan-18-21 08:46PM	Billionaire John Paulsons Top 10 Stock Picks Insider Monkey
Jan-11-21 07:00AM	Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (pegloticase injection) Trials Business Wire
Jan-08-21 02:23AM	The Horizon Therapeutics (NASDAQ:HZNP) Share Price Has Soared 428%, Delighting Many Shareholders Simply Wall St.
Jan-05-21 06:00AM	Get Ready for Health-Care Stocks to Go Wild. How to Play Them. Barrons.com
Dec-22-20 08:00AM	Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-17-20 06:40AM	Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production Business Wire -9.62%
Dec-15-20 04:13PM	United Therapeutics Meets 80-Plus RS Rating Benchmark; Hits New High Investor's Business Daily
10:40AM	Sangamo Therapeutics Sees RS Rating Rise To 85 And Composite Rating At 81 Investor's Business Daily
Dec-14-20 01:58PM	Intra-Cellular Therapies Getting Closer To Key Technical Benchmark Investor's Business Daily
Dec-09-20 10:42AM	Sarepta Therapeutics Sees Relative Strength Rating Improve To 74 Investor's Business Daily
Dec-07-20 01:57PM	Sarepta Therapeutics Earns Relative Strength Rating Upgrade Investor's Business Daily
01:11PM	Is HZNP A Good Stock To Buy Now? Insider Monkey
10:56AM	Top Pharmaceutical Stocks for Q1 2021 Investopedia
Dec-03-20 09:00AM	Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education Business Wire
Dec-02-20 09:15AM	Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List Business Wire
Dec-01-20 02:22AM	How Much Did Horizon Therapeutics' (NASDAQ:HZNP) CEO Pocket Last Year? Simply Wall St.
Nov-30-20 08:00AM	Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities Business Wire
Nov-25-20 08:00AM	Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire
Nov-23-20 08:00AM	Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire
08:00AM	Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology Business Wire
Nov-18-20 10:11AM	Investing Strategies: Horizon Therapeutics CEO, Chegg CFO, O'Neil Investment Strategist Share Insights Investor's Business Daily
Nov-17-20 09:15AM	National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation Business Wire
Nov-16-20 10:54AM	First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease Business Wire
Nov-13-20 10:40AM	Pacira Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
10:31AM	Atara Biotherapeutics Moves With Rising Relative Price Strength Investor's Business Daily
08:30AM	New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration Business Wire
08:00AM	Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala Business Wire
Nov-12-20 08:00AM	Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire
Nov-03-20 12:50AM	Horizon Therapeutics CEO On Success Of Key Drug Tepezza, Acquisition Plans Investor's Business Daily Video
Nov-02-20 04:15PM	Horizon Therapeutics Easily Tops Views, Hikes Outlook, But HZNP Stock Falls Investor's Business Daily
02:00PM	Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil Business Wire
08:12AM	Horizon Therapeutics: Q3 Earnings Insights Benzinga
07:00AM	Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance Business Wire
06:58AM	Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer Business Wire
Oct-30-20 09:15AM	Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year Business Wire
08:00AM	New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting Business Wire
Oct-29-20 03:17PM	AGC Biologics and Horizon Therapeutics plc Expand Partnership PR Newswire
03:00PM	AGC Biologics and Horizon Therapeutics plc Expand Partnership PR Newswire
02:25PM	Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
08:00AM	Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout Business Wire
Oct-26-20 10:04PM	Were Hedge Funds Right About Crowding Into Horizon Therapeutics (HZNP)? Insider Monkey
08:00AM	Horizon Therapeutics plc Named One of the Most Innovative Companies by Crains Chicago Business Business Wire
07:29AM	Here's Why I Think Horizon Therapeutics (NASDAQ:HZNP) Is An Interesting Stock Simply Wall St.
Oct-23-20 08:00AM	Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption Business Wire
Oct-22-20 10:00AM	New Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout Business Wire
Oct-20-20 08:00AM	Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award Business Wire -5.29%
Oct-16-20 11:05AM	Dow Jones, Nasdaq Reheat Rally As Stock Market Today Ushers New Breakouts Investor's Business Daily
08:30AM	FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year Business Wire
Oct-14-20 08:00AM	TEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED) Business Wire
Oct-09-20 06:14PM	Cannabis Use Is on the Rise. Where to Invest Now. Barrons.com
Oct-08-20 08:15AM	New Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020 Business Wire
08:00AM	Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020 Business Wire
Oct-07-20 08:00AM	Horizon Therapeutics plc Named One of San Francisco Bay Areas Best and Brightest Companies to Work For Business Wire
Oct-06-20 04:22PM	Dow Jones Sinks Over 375 Points After Trump Chills Stimulus Talks Investor's Business Daily
Oct-05-20 07:45PM	The 21-Day Exponential Moving Average: Why This Is Your New Edge Investor's Business Daily
08:00AM	Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award Business Wire
Oct-01-20 04:00PM	Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption Business Wire
Sep-29-20 08:00AM	Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Shares Could Be 35% Below Their Intrinsic Value Estimate Simply Wall St.
Sep-23-20 04:14PM	Horizon Therapeutics Stock Hits Record High As Sales Of Key Drug Top Views Investor's Business Daily
Sep-16-20 04:33PM	Stocks Today End Mixed; Two Of These Four Breakouts Undercut Their Buy Points Investor's Business Daily
12:19PM	Stocks Showing Market Leadership: Atara Biotherapeutics Earns 92 RS Rating Investor's Business Daily
08:00AM	MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate Business Wire
Sep-15-20 11:37AM	Horizon Therapeutics Is A Buy Investor's Business Daily Video
10:48AM	Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Sep-14-20 05:34PM	Dow Jones Futures: Stock Market Rally Gets A Win As Tesla, Nvidia Jump, Apple In Buy Zone; Tesla Rival Nikola Dives On SEC Probe Investor's Business Daily +8.59%
Sep-10-20 12:11PM	Sangamo Therapeutics Getting Closer To Key Technical Benchmark Investor's Business Daily
Sep-08-20 10:24AM	Hedge Funds Never Been This Bullish On Horizon Therapeutics (HZNP) Insider Monkey
Sep-03-20 10:23AM	Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Stock Is Going Strong: Is the Market Following Fundamentals? Simply Wall St.
Sep-02-20 09:00AM	Horizon Therapeutics plc Named to the 2020 PEOPLE "50 Companies That Care" List Business Wire
Sep-01-20 08:00AM	Horizon Therapeutics plc to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Aug-28-20 04:29PM	Horizon Therapeutics, IBD Stock Of The Day, Rides Rare-Disease Drug To Buy Points Investor's Business Daily
11:03AM	Horizon Therapeutics Sets Up Investor's Business Daily Video
Aug-27-20 09:56AM	Dow Jones Today, Stocks Mixed On Powell's 'Robust Update;' NetApp Stirs Database Stocks, Abbott Gets FDA Covid Nod Investor's Business Daily
Aug-26-20 01:33PM	Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DesJardin Michael A.	EVP, Technical Operations	Feb 26	Sale	91.83	1,099	100,921	86,247	Feb 26 06:12 PM
DesJardin Michael A.	EVP, Technical Operations	Feb 24	Sale	92.48	15,944	1,474,448	87,346	Feb 26 06:12 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Feb 22	Sale	87.22	5,698	496,987	81,677	Feb 23 06:19 PM
Karnani Vikram	EVP & President, International	Feb 22	Sale	87.19	8,358	728,722	104,165	Feb 23 06:20 PM
DesJardin Michael A.	EVP, Technical Operations	Feb 11	Sale	90.00	10,786	970,740	101,200	Feb 12 05:01 PM
DesJardin Michael A.	EVP, Technical Operations	Feb 02	Sale	85.00	4,530	385,050	111,986	Feb 04 05:39 PM
Walbert Timothy P	Chairman, President and CEO	Feb 01	Option Exercise	0.00	9,087	0	22,895	Feb 03 05:24 PM
Karnani Vikram	EVP & President, International	Jan 22	Sale	76.81	2,731	209,768	111,429	Jan 22 09:05 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Jan 22	Sale	76.81	2,226	170,979	86,500	Jan 22 09:04 PM
Walbert Timothy P	Chairman, President and CEO	Jan 22	Sale	76.47	11,323	865,917	946,559	Jan 22 08:59 PM
Camardo Daniel A.	EVP and President, U.S.	Jan 21	Option Exercise	0.00	3,220	0	46,503	Jan 22 09:09 PM
Beeler Brian K	EVP, General Counsel	Jan 21	Option Exercise	0.00	4,120	0	123,472	Jan 22 09:08 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	Jan 21	Option Exercise	0.00	3,590	0	35,206	Jan 22 09:08 PM
DesJardin Michael A.	EVP, Technical Operations	Jan 21	Option Exercise	0.00	3,678	0	118,340	Jan 22 09:06 PM
CURTIS GEOFFREY M.	EVP, Corporate Affairs, CCO	Jan 21	Option Exercise	0.00	3,760	0	87,205	Jan 22 09:07 PM
Karnani Vikram	EVP & President, International	Jan 21	Option Exercise	0.00	4,904	0	116,333	Jan 22 09:05 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Jan 21	Option Exercise	0.00	3,999	0	90,498	Jan 22 09:04 PM
MOZE BARRY	EVP, Chief Admin. Officer	Jan 21	Option Exercise	0.00	5,819	0	172,762	Jan 22 09:03 PM
Kent Jeff	See remarks	Jan 21	Option Exercise	0.00	3,045	0	71,468	Jan 22 09:02 PM
Hoelscher Paul W.	EVP, CFO	Jan 21	Option Exercise	0.00	5,556	0	6,605	Jan 22 09:01 PM
Walbert Timothy P	Chairman, President and CEO	Jan 21	Option Exercise	0.00	2,575	0	14,563	Jan 22 08:59 PM
Walbert Timothy P	Chairman, President and CEO	Jan 21	Option Exercise	0.00	20,330	0	966,889	Jan 22 08:59 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Jan 21	Option Exercise	0.00	5,353	0	81,361	Jan 22 09:00 PM
Walbert Timothy P	Chairman, President and CEO	Jan 15	Sale	77.89	211,204	16,449,893	946,559	Jan 15 05:43 PM
DesJardin Michael A.	EVP, Technical Operations	Jan 06	Option Exercise	16.35	27,106	443,296	141,768	Jan 08 05:32 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Jan 06	Sale	74.76	26,844	2,006,854	86,499	Jan 08 05:33 PM
Karnani Vikram	EVP & President, International	Jan 06	Sale	75.00	30,031	2,252,325	111,429	Jan 08 05:31 PM
DesJardin Michael A.	EVP, Technical Operations	Jan 06	Sale	75.00	27,106	2,032,950	114,662	Jan 08 05:32 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	Dec 14	Sale	80.00	1,856	148,480	19,741	Dec 15 05:00 PM
DesJardin Michael A.	EVP, Technical Operations	Dec 10	Sale	69.64	5,909	411,503	63,392	Dec 11 04:41 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Dec 08	Sale	71.15	40,764	2,900,354	174,955	Dec 09 05:05 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Dec 07	Sale	70.94	63,078	4,474,860	215,719	Dec 09 05:05 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	Nov 12	Sale	75.48	12,124	915,120	21,597	Nov 13 07:27 PM
Camardo Daniel A.	EVP and President, U.S.	Nov 06	Sale	76.76	3,500	268,663	30,829	Nov 06 06:00 PM
Kent Jeff	See remarks	Nov 05	Sale	78.94	47,944	3,784,663	51,049	Nov 06 06:00 PM
MOZE BARRY	EVP, Chief Admin. Officer	Nov 05	Sale	78.93	77,500	6,117,259	100,709	Nov 06 06:00 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Oct 21	Option Exercise	7.61	13,000	98,930	28,015	Oct 21 05:06 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Sep 17	Option Exercise	14.05	21,351	299,982	57,373	Sep 18 05:00 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Sep 16	Sale	78.88	8,919	703,531	36,022	Sep 18 05:00 PM
Beeler Brian K	EVP, General Counsel	Sep 04	Option Exercise	14.91	28,143	419,666	64,028	Sep 08 04:51 PM
Hoelscher Paul W.	EVP, CFO	Aug 24	Sale	75.76	29,576	2,240,702	102,925	Aug 25 05:16 PM
Walbert Timothy P	Chairman, President and CEO	Aug 06	Sale	72.54	110,000	7,979,414	733,792	Aug 07 05:42 PM
GREY MICHAEL G	Director	Aug 05	Option Exercise	3.95	1,755	6,932	1,755	Aug 07 05:40 PM
GREY MICHAEL G	Director	Aug 05	Sale	73.35	1,755	128,729	0	Aug 07 05:40 PM
Karnani Vikram	EVP & President, International	Aug 03	Option Exercise	13.15	36,772	483,636	78,941	Aug 05 01:24 PM
SANTINI GINO	Director	Aug 03	Option Exercise	2.88	35,795	103,262	35,795	Aug 04 04:56 PM
GREY MICHAEL G	Director	Jul 22	Option Exercise	3.95	1,755	6,932	1,755	Jul 22 05:33 PM
GREY MICHAEL G	Director	Jul 22	Sale	60.00	1,755	105,300	0	Jul 22 05:33 PM
Kent Jeff	See remarks	Jul 07	Option Exercise	5.68	38,000	215,980	98,993	Jul 07 06:57 PM
MOZE BARRY	EVP, Chief Admin. Officer	Jul 07	Option Exercise	13.17	35,076	461,918	178,209	Jul 07 06:50 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Jul 06	Sale	57.50	9,100	523,250	278,797	Jul 07 06:49 PM
MOZE BARRY	EVP, Chief Admin. Officer	Jul 01	Sale	54.64	23,158	1,265,441	143,133	Jul 02 04:46 PM
GREY MICHAEL G	Director	Jun 25	Option Exercise	3.95	1,755	6,932	1,755	Jun 26 05:00 PM
GREY MICHAEL G	Director	Jun 25	Sale	55.00	1,755	96,525	0	Jun 26 05:00 PM
Kent Jeff	See remarks	Jun 10	Sale	48.05	2,785	133,819	60,993	Jun 12 06:00 PM
Kent Jeff	See remarks	Jun 01	Sale	49.94	57,215	2,857,179	60,994	Jun 02 06:18 PM
Karnani Vikram	EVP, Chief Commercial Officer	Jun 01	Sale	50.23	2,369	118,995	42,169	Jun 02 06:17 PM
Beeler Brian K	EVP, General Counsel	Jun 01	Sale	50.23	2,370	119,045	35,885	Jun 02 06:16 PM
CURTIS GEOFFREY M.	EVP, Corporate Affairs, CCO	May 26	Sale	49.85	21,918	1,092,612	34,834	May 27 05:00 PM
GREY MICHAEL G	Director	May 22	Option Exercise	7.84	10,530	82,555	10,530	May 26 05:00 PM
GREY MICHAEL G	Director	May 22	Sale	48.77	10,530	513,505	0	May 26 05:00 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	May 11	Option Exercise	4.96	33,479	166,056	47,445	May 12 04:12 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	May 11	Sale	45.00	33,479	1,506,555	13,966	May 12 04:12 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	May 11	Sale	44.22	49,114	2,171,585	30,816	May 12 04:11 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	May 08	Sale	43.51	45,366	1,973,711	79,930	May 12 04:11 PM
DesJardin Michael A.	EVP, Technical Operations	May 07	Option Exercise	14.93	23,159	345,764	64,359	May 07 04:29 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	May 06	Option Exercise	14.05	59,794	840,106	95,183	May 07 04:31 PM
Beeler Brian K	EVP, General Counsel	May 06	Sale	40.80	48,000	1,958,515	37,206	May 07 04:32 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	May 06	Sale	41.19	59,794	2,462,915	35,389	May 07 04:31 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	May 06	Sale	41.19	3,545	146,019	129,095	May 07 04:30 PM
DesJardin Michael A.	EVP, Technical Operations	May 06	Sale	41.59	17,959	747,004	41,200	May 07 04:29 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	May 05	Sale	37.00	5,007	185,259	132,640	May 07 04:30 PM
DesJardin Michael A.	EVP, Technical Operations	May 05	Sale	38.00	8,980	341,240	59,159	May 07 04:29 PM
Hoelscher Paul W.	EVP, CFO	May 05	Sale	38.00	104,994	3,989,772	132,501	May 07 04:27 PM
Beeler Brian K	EVP, General Counsel	Apr 29	Sale	35.02	15,880	556,118	85,206	Apr 30 05:50 PM
Karnani Vikram	EVP, Chief Commercial Officer	Apr 29	Sale	35.00	15,683	548,905	43,489	Apr 30 05:49 PM
Karnani Vikram	EVP, Chief Commercial Officer	Apr 28	Sale	35.01	30,063	1,052,506	59,172	Apr 30 05:49 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Apr 20	Sale	34.13	19,886	678,685	35,389	Apr 21 05:00 PM
Beeler Brian K	EVP, General Counsel	Apr 16	Sale	32.51	9,000	292,615	101,086	Apr 17 04:23 PM
Beeler Brian K	EVP, General Counsel	Apr 07	Sale	32.50	297	9,653	110,086	Apr 08 04:46 PM
Beeler Brian K	EVP, General Counsel	Apr 06	Sale	32.50	2,370	77,025	110,383	Apr 08 04:46 PM
MOZE BARRY	EVP, Chief Admin. Officer	Mar 30	Option Exercise	12.94	2,106	27,252	168,397	Mar 31 05:01 PM
MOZE BARRY	EVP, Chief Admin. Officer	Mar 30	Sale	28.18	2,106	59,347	166,291	Mar 31 05:01 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Mar 11	Option Exercise	12.94	5,287	68,414	13,966	Mar 13 04:15 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience